Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18667654 | 0.85 | ALDH1A1 (0.35) | MAPK1ALDH1A1CYP1A2THRBHPGD | |
| SCHEMBL17071238 | 0.85 | NPSR1 (0.37) | NPSR1 | |
| SCHEMBL18667691 | 0.85 | ATM (0.41) | MAPK1ALDH1A1CYP1A2THRBHPGD | |
| SCHEMBL17071175 | 0.84 | NPSR1 (0.38) | NPSR1LMNA | |
| SCHEMBL18668049 | 0.83 | CYP1A2 (0.35) | NPSR1MAPK1ALDH1A1CYP1A2THRB | |
| SCHEMBL19046786 | 0.83 | NPSR1 (0.41) | NPSR1MAPK1ALDH1A1HSD17B10LMNA | |
| SCHEMBL18668051 | 0.82 | NPSR1 (0.36) | NPSR1MAPK1LMNA | |
| SCHEMBL18668062 | 0.81 | ATM (0.46) | MAPK1ALDH1A1CYP1A2THRBHPGD | |
| SCHEMBL22187491 | 0.81 | L3MBTL1 (0.37) | ALDH1A1CYP1A2 | |
| SCHEMBL20311795 | 0.80 | HPRT1 (0.35) | MAPK1ALDH1A1CYP1A2THRBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10421721-B2 | Heterocyclic compound and organic light emitting device comprising same | LG CHEM, LTD. (KR) | 2019-09-24 | — | — | US | disclosed |
| US-20180037547-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-02-08 | — | — | US | disclosed |
| US-20180037547-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-02-08 | — | — | US | disclosed |
| WO-2017047992-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | 주식회사 엘지화학 | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10421721-B2 | Heterocyclic compound and organic light emitting device comprising same | CRY1, CRY2, PER2 | NPSR1 3589/4885MAPK1 4452/4885ALDH1A1 486/4885 |
| US-20180037547-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | CRY1, CRY2, PER2 | NPSR1 3589/4885MAPK1 4452/4885ALDH1A1 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.